Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, Glucagon May 16 | 2019Zealand Q1 '19 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i May 15 | 2019JNJ 2019 Pharmaceutical Business ReviewPurchase Blast
Free
Posted in: Dual/triple agonist, GLP-1RA May 15 | 2019Lilly oral dual agonist comments @ BAMLAccess Free Blast
$599
Posted in: Glucagon May 14 | 2019Zealand's Dasiglucagon Filing Delayed; Positive Ph3 Dasiglucagon Topline ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Insulin Delivery May 13 | 2019FDA Issues Final Guidance on Biosimilar InterchangeabilityPurchase Blast
$599
Posted in: GLP-1RA May 13 | 2019FENIX Analysis: GLP-1RA Promotional Materials Post-AACE 2019Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i May 10 | 2019ADA 2019 Abstract and Session Titles AvailablePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery May 09 | 2019Senseonics, BD, and Xeris Q1 '19 Earnings UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist May 07 | 2019LY3305677 Lilly's Oxyntomodulin? New Ph1 Trial ObservedPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA May 07 | 2019Novo Q1 '19 London Earnings UpdatePurchase Blast
$599
Posted in: DPP-IVi, SGLT2i May 03 | 2019AZ Triple Combo Approved as Qternmet XR; Qtern Label UpdatePurchase Blast$599
Posted in: Basal Insulin, GLP-1RA May 03 | 2019Tresiba Hypo Benefit Over Toujeo; Novo Q1 '19 Earnings UpdatePurchase Blast
$599
Posted in: SGLT2i May 01 | 2019No Update on Sota CRL Resolution Timeline; Lexicon Q1 '19 Earnings UpdatePurchase Blast
$599
Posted in: DPP-IVi, GLP-1RA, SGLT2i Apr 30 | 2019Merck and Pfizer Q1 '19 Earnings UpdatesPurchase Blast
Free
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i Apr 30 | 2019REWIND Filed; Empa T1DM, Nasal Glucagon Delayed; Lilly Q1 '19 Earnings UpdateAccess Free Blast
$599
Posted in: GLP-1RA Apr 29 | 2019Victoza Pediatric Trial (ELLIPSE) Results and Regulatory FilingsPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
